In 2004, two landmark studies identified a causal role of EGFR mutations in NSCLC, where EGFR mutations correlated with patient responsiveness to Gefitinib therapy, and also, with growth inhibition by Gefitinib in NSCLC cell lines [39,51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.